In brain tumors, breast cancer, ovarian cancer, gastric cancer, and esophageal cancer, the SFRP2 promoter is hypermethylated, suggesting SFRP2 may act as a tumor suppressor (130). This evidence concerns the gene SFRP2 and ovarian carcinoma.